Furthermore, research has demonstrated the Ki-67 index may be clinically significant for predicting neoadjuvant chemotherapy effectiveness in stage I-IIIA NSCLC and chemotherapy responses in advanced NSCLC (10, 11). This evidence concerns the gene MKI67 and non-small cell lung carcinoma.